1. Introduction {#s0005}
===============

Current guidelines recommend the use of unenhanced chest computed tomography (CT) as first-line imaging in patients suspected of having COVID-19 pneumonia, in order to assess the extent of lung damage \[[@bb0005],[@bb0010]\]. Although most patients have a favorable disease course, some of them develop secondary disease worsening due to an excessive systemic inflammatory response, evidenced by high serum levels of biomarkers such as IL-6, which promotes an hypercoagulability state leading to thrombotic complications \[[@bb0015],[@bb0020]\]. A D-dimer level greater than 1000 μg/L has been clearly identified as a risk factor for poor outcome \[[@bb0025]\].

However, little is known about the exact prevalence of thromboembolism in COVID-19 patients. Recent studies \[[@bb0030], [@bb0035], [@bb0040]\] have reported a high cumulative incidence of acute pulmonary embolism (PE), ranging from 23% to 30%, but these reports mainly concerned severe patients admitted in ICU. To date, the prevalence of acute PE at baseline presentation of unselected COVID-19 patients remains unknown, as is the benefit of a systematic CT pulmonary angiography (CTPA) at initial screening.

The objective of this study was to evaluate the prevalence of PE when systematically performing CT pulmonary angiography (CTPA) as first-line imaging modality in patients with COVID-19 suspicion.

2. Materials and methods {#s0010}
========================

This retrospective study was approved by the local ethics committee of Saint-Etienne, which waived the need for patient consent.

2.1. Patient population and data {#s0015}
--------------------------------

From March 26th, 2020, following the reports of frequent PE in COVID-19 patients \[[@bb0045],[@bb0050]\], it was decided to systematically perform CTPA as first-line imaging modality in patients suspected of COVID-19 at Saint-Etienne University Hospital, unless there were contraindications to contrast medium administration. We retrospectively included all consecutive patients suspected of COVID-19 presenting at the emergency department who had undergone systematic CTPA between March 26th and April 17th, 2020.

All patients had reverse transcriptase - polymerase chain reaction (RT-PCR) nasopharyngeal swab test for SARS-Cov-2 on the same day as the CTPA. In case of first negative RT-PCR result and high clinical suspicion, swab test was repeated.

Demographics, clinical and biological data as well as patients\' outcomes were collected from medical charts. The evaluated clinical parameters included age, sex, comorbidities (obesity, type 2 diabetes, respiratory or cardiovascular disease, hypertension), delay from symptoms onset as well as for oxygen needs, ICU admission or mechanical ventilation. Biological data included D-dimer, C-reactive protein, lactate dehydrogenase levels and lymphocyte count.

Patients with a single negative RT-PCR result, who had typical CT features of COVID-19 pneumonia in addition to suggestive symptoms and laboratory results were considered as COVID-19 positive.

Cases of contrast medium extravasation after intravenous administration or of serum creatinine increase in the following days after CTPA were reported.

2.2. CT protocol and imaging analysis {#s0020}
-------------------------------------

CT examinations were performed on a multidetector CT scanner using routine CTPA protocols. Images were acquired after intravenous administration of 50--70 mL of nonionic iodinated contrast media at a flow rate of 4 mL/s, using automatic detection of the contrast bolus in the pulmonary trunk, and reconstructed with 1-mm slice thickness. Images were analyzed on Picture Archiving and Communication System workstations (Carestream Vue PACS, version 12.1.5) by an experienced chest radiologist, aware of the COVID-19 suspicion but blinded to clinical and biological data. CT images were evaluated for signs of COVID-19 pneumonia, lung disease extent and presence of pulmonary embolism. For COVID-19 positive scans, disease extent was classified into 4 categories according to the percentage diseased lung: mild (\<25%), moderate (25--50%), severe (50--75%) or critical (\>75%) involvement. Signs of right ventricular dysfunction (right-to- left ventricle diameter ratio \> 1, paradoxical septal bowing) were reported for PE positive cases.

2.3. Statistical analysis {#s0025}
-------------------------

Statistical analysis was performed using the statistical software package "R" (version 3.2.1, R Foundation, Vienna, Austria). Demographics, clinical and biological between patients with and without PE were compared using *t-*test and Fisher exact test. Disease extent was compared using a Cochran-Armitage trend test. *P* values less than 0.5 were considered as statistically significant.

3. Results {#s0030}
==========

[Fig. 1](#f0005){ref-type="fig"} shows the flowchart of the study. Patient characteristics are presented in [Table 1](#t0005){ref-type="table"} .Fig. 1Flowchart of the study.Fig. 1Table 1Patient characteristics.Table 1All COVID-19 patientsCOVID-19 patients without PECOVID-19 patients with PEP value(*n* = 70)(*n* = 66)(*n* = 4)Age (years)65 ± \[21--97\]65 ± 16 \[21--97\]69 ± 3 \[66--73\]0.226Male44/70 (63)41/66 (62)3/4 (75)1.0Positive RT-PCR65/70 (93)61/66 (92)4/4 (100)1.0Delay from onset of symptoms to CT (days)8 ± 4 \[1--16\]8 ± 4 \[1--16\]6 ± 2 \[4--8\]0.354  ComorbiditiesOverweight or obesity34/54 (63)30/50 (60)4/4 (100)0.285Type 2 diabetes14/68 (21)12/64 (19)2/4 (50)0.185Hypertension31/68 (46)27/64 (42)4/4 (100)**0.039**Smoking history18/67 (27)16/63 (25)2/4 (50)0.291Respiratory disease9/68 (13)9/64 (14)0/4 (0)1.0Cardiovascular Disease14/68 (21)13/64 (20)1/4 (25)1.0  CT disease extent[⁎](#tf0005){ref-type="table-fn"}Absent3/70 (4)3/66 (5)0/4 (0)Mild36/70 (51)35/66 (53)1/4 (25)Moderate22/70 (31)20/66 (30)2/4 (50)Severe5/70 (7)5/66 (8)0/4 (0)Critical4/70 (6)3/66 (5)1/4 (25)  Disease severityOxygen therapy38/68 (56)34/64 (53)4/4 (100)0.124ICU16/70 (23)13/66 (20)3/4 (75)**0.035**Mechanical ventilation12/70 (17)10/66 (15)2/4 (50)0.133Death1/68 (1)1/64 (2)0/4 (0)1.0  Laboratory analysisD dimer (μg/L)1694 ± 2890 \[270--20,000\]1102 ± 538 \[270--2210\]9394 ± 7024 \[988--20,000\]0.133D dimer \>5000 μg/L3/56 (5)0/52 (0)3/4 (75)\<**0.001**CRP (mg/L)84 ± 72 \[0--315\]77 ± 62 \[0--263\]198 ± 118 \[53--315\]0.176CRP \> 25 mg/L55/69 (80)51/65 (78)4/4 (100)0.575LDH (UI/L)413 ± 163 \[197--1181\]407 ± 166 \[197--1181\]488 ± 90 \[355--608\]0.226LDH \> 250 UI/L48/54 (89)44/50 (88)4/4 (100)1.0Lymphopenia43/69 (62)40/65 (62)3/4 (75)1.0[^1]

Of the 199 patients who underwent CTPA, 70 were positive for COVID-19: 65 had a positive RT-PCR result whereas 5 other patients with typical CT features of COVID-19 pneumonia and only one negative RT-PCR result were also considered positive.

Four (4/70, 5.7%) of the COVID-19 patients had acute PE: 2 had segmental PE, one had lobar PE and the last patient a proximal defect in the right main pulmonary artery, with signs of right ventricular dysfunction.

Eleven (11/129, 8.5%) of the 129 COVID-19 negative patients had acute PE, at the segmental level in seven patients, lobar level or more proximal level in four, two with signs of right ventricular dysfunction.

PE prevalence was not significantly different between patients with and without COVID-19 (*p* = 0.581).

Although disease extent was not significantly different between the PE positive and negative groups, COVID-19 patients with PE were more frequently admitted in ICU. Hypertension was more frequent in the PE positive group.

Of the 70 COVID-19 positive patients, 44 had abnormal age-adjusted D-dimer levels, but the proportion of those having D-dimer level \> 5000 μg/L was significantly higher in patients with PE.

Regarding complications of contrast administration, 3 of the 199 patients who underwent CTPA presented contrast extravasation and 3 elderly patients (mean age 85.3 ± 4.7), of which 2 had type 2 diabetes, presented subsequent increase of the serum creatinine above 614 ± 100 μmol/L, resulting in a 3.0% (6/199) complication rate following contrast medium administration.

4. Discussion {#s0035}
=============

Since the outbreak of the COVID-19 epidemic, the impact of unenhanced chest CT has been widely reported and is no longer discussed \[[@bb0055],[@bb0060]\]. Given the high risk of pulmonary embolism in the COVID-19 pneumonia, first-line CTPA is an option that deserves to be considered. To the best of our knowledge, this is the first study reporting PE prevalence in unselected COVID-19 patients at initial presentation. Previous studies on PE mainly concerned severe COVID-19 patients admitted to ICU. Our study shows that the prevalence of acute PE at initial presentation is low, below 6%, and not different from that observed for COVID-19 negative patients.

Dyspnea and desaturation are common symptoms of both COVID-19 and pulmonary embolism, and clinical triage is difficult. Furthermore, the Wells or Geneva pre-test probability scores usually used for outpatients with PE suspicion have not been validated for COVID-19 patients. Most patients with SARS-Cov2 infection had elevated D-dimers, but a value above 5000 μg/L was only observed in patients with PE. Even if it is not possible to draw a definitive conclusion on a limited series, our data suggest considering contrast administration at initial presentation of patients with COVID-19 suspicion who have marked elevation of D-dimers.

There was a 7-day median interval between symptoms onset and CTPA in our study which is shorter than that reported (12 to 14 days) in studies reporting 23% to 30% cumulative incidence of PE in COVID-19 patients \[[@bb0030],[@bb0040]\]. These results support the hypothesis of a delayed hypercoagulability state, occurring during the second phase of the disease consecutively to the cytokine release syndrome \[[@bb0015]\].

Although complications of iodinated contrast administration were rarely observed in our study, a significant deterioration of the renal function occurred for 3 elderly patients. SARS-Cov-2 can deteriorate the renal function following direct endothelial invasion of the glomerular capillaries. Thus, routine use of contrast administration should be carefully considered in COVID-19 patients, especially if there are risk factors for renal function deterioration such as diabetes or advanced age.

This study has several limitations, including its retrospective nature, the small number of events and the lack of follow-up especially regarding late thromboembolic events. Nonetheless, we believe that the present study improves the current knowledge on COVID-19 disease, by reporting a low PE prevalence at initial presentation.

To conclude, this study does not provide clear evidence that there is a benefit to routinely perform CTPA as first-line imaging modality in patients suspected of COVID-19 pneumonia.
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[^1]: Cochran-Armitage trend test.
